Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $218M (up 33.6% year over year) with net income of $78M.
Q2 2026 key financials · XBRL
- Revenue
- $218M
- +33.6% YoY · +39.5% QoQ
- Net income
- $78M
- +1441.7% YoY · +110.9% QoQ
- Operating margin
- 45.1%
- EPS (diluted)
- $0.39
- +1850.0% YoY · +113.1% QoQ
Source: XBRL data from the BIOCRYST PHARMACEUTICALS INC (BCRX) Q2 2026 10-Q on SEC EDGAR. USD.
BIOCRYST PHARMACEUTICALS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $218.25M vs $163.35M YoY, up $54.9M
- ORLADEYO revenue $158.20M vs $156.84M YoY
- License and other revenue $60.05M vs $6.52M, including $55.7M Neopharmed recognition
- Neopharmed agreement: $70.0M upfront consideration, up to $275.0M milestones, 18%-30% royalties
- Birmingham Closure Plan: discovery programs discontinued, implementation substantially complete by end-2026
Risk Factors
- Sustained profitability risk: 2025 marked first annual U.S. GAAP net income, but profitability remains unproven
- Royalty obligations: ORLADEYO revenues subject to RPI and OMERS payments under Royalty Purchase Agreements
- Commercialization risk: profitability depends on patient and physician acceptance, reimbursement levels, and competition
- Execution risk: inaccurate capital-allocation forecasts could undermine operational and budget plans
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BIOCRYST PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.